Single agent chemotherapy

DRUG3 trials

Sponsors

AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Inc.

Conditions

Non-small cell lungcancerRelapsed Ovarian Cancer, BRCA Mutation, Platinum SensitivitySmall Cell Lung Carcinoma (SCLC)

Phase 1

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

Active, not recruitingNCT05990738

Boehringer IngelheimSmall Cell Lung Carcinoma (SCLC)

Start: 2024-02-14End: 2027-07-30Updated: 2026-03-31

Phase 3

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

CompletedNCT02282020

AstraZenecaRelapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

Start: 2015-02-06End: 2022-07-19Updated: 2022-07-26

TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy

Active, not recruitingNL-OMON43590

Clovis Oncology, Inc.Non-small cell lungcancer

Start: 2015-05-04Target: 27Updated: 2024-02-28

Related Papers

DAREONTM-9, a phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): Interim analysis results.

Journal of Clinical Oncology2025-05-281 citations

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results

Journal of Clinical Oncology2024-12-134 citations

LB001/#1731 Late-breaking abstract presentation: overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3

2022-12-017 citations

BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer.

Journal of Clinical Oncology2022-06-0114 citations

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

Journal of Clinical Oncology2020-02-19287 citations

33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial

2019-09-017 citations

Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

Journal of Clinical Oncology2019-05-2026 citations

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.

2016-11-0840 citations

SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline <i>BRCA1/2</i> mutation (g<i>BRCA</i>m).

Journal of Clinical Oncology2016-05-209 citations